Pfizer Looks for FDA Approval of COVID Vaccine Booster for All Adults

Pfizer Inc. and BioNTech on Tuesday requested the US Food and Drug Administration (FDA) authorize booster doses of their COVID-19 vaccine in all adults.

Pfizer has presented recent data showing the shot would help prevent the disease across ages. Over the past several months, the FDA has authorized Pfizer's boosters for people who are immunocompromised, those who are aged 65 and above, all people at high risk of severe disease, and people regularly exposed to the virus.

Pfizer previously requested authorization for all people aged 16 or over, but the FDA held back due to a lack of evidence of waning immunity or of the benefit of boosters in younger people.

In turn, the pharmaceutical company said it would present data from a large clinical study which last month showed that a booster dose of its vaccine was 95.6% effective against the coronavirus when compared to a vaccinated group that did not get the third shot.

Moderna too is likely to file a request with the US FDA to broaden emergency use authorization of its boosters in all adults. So far, the competitor booster doses (Moderna and Johnson & Johnson) have been cleared for use in a similar group of patients to Pfizer’s. 

*The products advertised are only available to clients under Fondex Limited (SDL No: SD037). Trading CFDs involves significant risk of loss.